Final answer:
To reduce dyskinesia in Parkinson's patients on carbidopa/levodopa therapy, targeting the NR2B subunit of NMDA with compounds like CP-101,606 could be effective. Long-term L-DOPA therapy can lead to dyskinesia due to changes in NMDA receptor subunit composition. A healthcare provider should be consulted for appropriate treatment.
Step-by-step explanation:
To decrease the long-term effects of dyskinesia in a patient with Parkinson's disease on carbidopa/levodopa therapy, a medication targeting the NR2B subunit of the NMDA receptor, such as CP-101,606 (Traxoprodil), could be considered. While this compound was effective in treating dyskinetic symptoms in human trials, it is vital to consult with the patient's healthcare provider for suitability and management of potential side effects.
It's important to note that dyskinesia is a possible complication of long-term L-DOPA use, as the patient becomes less responsive to treatment.Currently, L-DOPA is the most commonly prescribed medication for Parkinson's disease. It works by increasing dopamine levels in the striatum to compensate for the loss of dopaminergic neurons.However, prolonged use can alter NMDA receptor subunit composition, contributing to the development of L-DOPA induced dyskinesia.